Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

Frustration permeated the cannabis industry’s response to Health Canada when the federal agency released final regulations for marijuana-infused foods, drinks and vape products last Friday. Everett Knight, however, was rather pleased.

“These rules are exactly in line with our hopes and our expectations,” the executive vice president of Valens GroWorks, a Kelowna-based company focused exclusively on cannabis extract-based products, told Cannabis Professional shortly after the rules were published.

As had been outlined in the draft rules released in December, the new regulations prohibit making cannabis-infused foods in the same building as other food products or bottling cannabis-infused beverages in the same facility as other drinks.

Story continues below advertisement

That’s good news for companies like Valens, Barrie, Ont.-based MediPharm Labs, or Vancouver-Island based HollyWeed North that are building large portions of their business models around white labelling, whereby they produce extract-based products on behalf other companies who simply do the branding and marketing for the products.

“If you are one of the very few that are setting up your facility to do white-label manufacturing for all those people who have the product ideas, you now have a treasure trove of potential customers and clients," said Chad Finklestein, a lawyer with Dale & Lessmann LLP.

“There are so many companies that want to capitalize on the market for edibles, ingestibles, concentrates, whether it is CBD or THC, and they have ideas, but they aren’t necessarily going to be doing any manufacturing themselves,” Mr. Finklestein said.

Neither MediPharm, HollyWeed, nor Valens actually cultivate cannabis directly, instead focusing on extraction and product formulation. Valens has supply agreements with 10 major producers such as Canopy Growth, Tilray and Organigram. MediPharm also works with Canopy, as well as Supreme Cannabis and Indiva among others. Hollyweed announced its first extraction contact with Canopy in March. These agreements usually involve either the producer paying a fee for the processor to take dried flower and return concentrate or the processor buying wholesale cannabis from the producer for use in white label production.

In April, MediPharm announced that it had signed its first white-label deal with a non-cannabis firm, although it declined to name its partner.

Maintaining the separate kitchen requirements “is a huge step up for us,” Mr. Knight said, noting Valens has just started construction on a 36,000 sq ft facility in Kelowna that “is really a white label manufacturing operation.”

“Everything we learned [from the final regulations] just secures the advantage we already had,” he said.

Story continues below advertisement

MediPharm just completed a bought deal financing that raised $75-million, which was increased from the original size of $60-million due to strong demand. In a note to clients published Monday morning about the company’s fundraising, GMP Securities analyst Ryan Macdonell said the regulations Health Canada published last week means “a hurdle has been lifted for the signing of white-labelling contracts.”

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies